Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.49 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331160 | 0.92 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL383793 | 0.89 | SCN9A (0.47) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL386363 | 0.83 | SCN9A (0.52) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Hydrochloric Acid SCHEMBL384753 | 0.82 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12315029 | 0.81 | SCN9A (0.49) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL17169516 | 0.81 | SCN9A (0.49) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281281 | 0.80 | SCN9A (0.69) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280965 | 0.80 | SLC6A12 (0.62) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281454 | 0.80 | SCN9A (0.61) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281032 | 0.80 | SCN9A (0.54) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | claimed |
| EP-2350091-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.